Infectious Disease Pt 3 (Antifungals, Antivirals) Flashcards
Antifungals
- Treat disease causing y____ and m___
- Common classes
- P______ (amphotericin B)
- T______ (fluconazole)
- E______ (Micafungin)
- Common pathogens (2)
- yeast, mold
- Polyenes
- Triazoles
- Echinocandins
- Candida, Aspergillus species
Indications for Antifungal Therapy
- Invasive ________
- Mucocutaneous disease, Candiduria, Candidemia (4th most common blood stream infection), Intra-abdominal infections, Meningitis, Endocarditis
- Invasive ____ infections (lung, sinus, skin, CNS)
- Aspergillosis, Other mold species
- Candidiasis
- Mold
Triazoles Spectrum of Activity
+Fluconazole (Diflucan)
- Bioavailability
- __\_ azole that concentrates well in ____
- Think: _______ infections (3)
- Given as a ___ time dose for _____ infection
- Excellent oral bioavailability
- ONLY, urine
- Candida albicans (thrush, UTI, blood)
- one, yeast
+Voriconazole (VFEND)
- Drug of choice for?
- Excellent distribution, except for ____\_
- Routes (____ bioavailability)
- Requires _____
- Goal __-__ mcg/ml
- SE (2)
- Do not make mistake of using voriconazole for (1)
- pulmonary aspergillos
- urine
- PO, IV (great)
- Monitoring
- 2 - 5.5
- Visual disturbances, Hallucinations (SE at high doses)
- Drug resistant fungal UTIs
+Antivirals
(3)
Routes
Acyclovir (Zovirax) IV, PO
Valacyclovir (Valtrex) PO
Oseltamivir (Tamiflu)
+Acyclovir, Valacyclovir
MOA
Inhibits DNA replication
+Acyclovir, Valacyclovir
SE
- ___________ with IV formulation if not well ____ (carefully monitor ____ function and administer bolus or continuous ____)
Well tolerated (main SE: HA, Nausea)
- Nephrotoxicity, hydrated, renal, fluids
- These drugs can crystallize in the urine -> nephrotoxic*
+Valacyclovir
What is it?
Half life:
Dosing:
Prodrug -> converted to acyclovir
longer
less frequently
Acyclovir requires frequent dosing -> low compliance
+Oseltamavir (Tamiflu)-Influenza
- MOA
- For better outcomes: _____ tx (within __-__hrs)
- Dosing Prophylaxis:
- Dosing Treatment:
- SE?
- Neuraminidase inhibition (halts replication)
- early (24-48)
- 1x/day
- 2x/day
- N/V (well tolerated)
Therapy based on culture data
Definitive Therapy
Therapy based on no culture data to guide abx selection
Takes into account (3)
Empiric Therapy
common pathogens, pt hx, local resistance
+Treatment of CAP, OUTPATIENT
- First line (uncomplicated) (2)
- First line (allergy or complicated) (2)
Duration: __ days
Complicated = pt has multiple _____ including either (3) OR (1)
- Azithromycin, Doxycycline
- Levofloxacin, Moxifloxacin
5 days
comorbities (COPD, DM, CHF), recent abx use